Comparison 4. PERPHENAZINE vs ARIPIPRAZOLE.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early: 1. Any reason	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.50, 1.11]
2 Leaving the study early: 2. Due to adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.53 [0.27, 1.05]
3 Leaving the study early: 3. Due to relapse / worsening or no improvement	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.34, 2.08]
4 Global state: 1. Change over time ‐ no better or deterioration (ITT)	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 short term	1	294	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.89, 1.17]
5 Global state: 2. Average endpoint score (CGI‐S)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 short term	1	294	Mean Difference (IV, Random, 95% CI)	‐0.20 [‐0.56, 0.16]
6 Mental state: 2a. State ‐ BPRS score reduction ('no effect')	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 less than 25% reduction ‐ short term	1	65	Risk Ratio (M‐H, Random, 95% CI)	1.45 [0.26, 8.14]
7 Mental state: 2b. State ‐ PANSS: mean endpoint from baseline (high = poor)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 total ‐ short term	1	65	Mean Difference (IV, Random, 95% CI)	1.38 [‐2.66, 5.42]
7.2 positive ‐ short term	1	65	Mean Difference (IV, Random, 95% CI)	0.63 [‐0.80, 2.06]
7.3 negative ‐ short term	1	65	Mean Difference (IV, Random, 95% CI)	0.33 [‐1.46, 2.12]
8 Mental state: 2c. State ‐ PANSS total change score (high = poor, skewed data)			Other data	No numeric data
8.1 short term			Other data	No numeric data
9 Adverse events: Movement disorders	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 akathisia ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	2.29 [0.89, 5.85]
9.2 EPS ‐ short term	2	365	Risk Ratio (M‐H, Random, 95% CI)	1.65 [0.70, 3.88]
9.3 use of antiparkinsonian drugs ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	1.56 [1.01, 2.41]
10 Adverse events: Movement disorders ‐ TESS total score (high = poor, skewed data)			Other data	No numeric data
10.1 short term			Other data	No numeric data
11 Other adverse events: 1. Arousal	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
11.1 agitation ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.63, 1.77]
11.2 anxiety ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	1.19 [0.63, 2.24]
11.3 insomnia ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.56, 1.31]
11.4 sleepiness/sedation ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	2.64 [0.85, 8.22]
12 Other adverse events: 2. Cardiovascular	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
12.1 faintness, dizziness, weakness ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	5.27 [1.18, 23.66]
13 Other adverse events: 3. Central nervous system	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
13.1 headache ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.29, 1.03]
14 Other adverse events: 4. Gastrointestinal	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
14.1 dyspepsia ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.59 [0.27, 1.30]
15 Other adverse events: 5. lab data	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
15.1 ECG abnormality (1st degree atrioventricular block)	1	300	Risk Ratio (M‐H, Random, 95% CI)	15.82 [2.12, 118.27]
15.2 prolactin: clinically significant high levels	1	300	Risk Ratio (M‐H, Random, 95% CI)	12.66 [6.06, 26.45]
15.3 prolonged QTc interval (≥450 msec and ≥10% increase from baseline) ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
16 Other adverse events: 6. any serious adverse event	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
16.1 short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.49, 1.28]
16.2 psychosis ‐ short term	1	300	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.29, 1.40]